Close Menu

Hologic

Hologic and LabCorp became the third and fourth commercial test makers to receive EUA designation for  assays to detect the coronavirus that causes COVID-19.

BioMérieux had alleged infringement of two of its patents associated with nucleotide sequences to detect HIV-1 subtypes. 

Firms like LabCorp, Quest, and BioReference have launched tests but a lack of clarity around demand presents challenges for assessing what capacity is needed.

The Department of Health and Human Services selected the diagnostic test for development support through a streamlined process called an easy broad agency announcement.

Hologic said laboratories may leverage the random-access and open-access capabilities of its Panther Fusion system to broaden screening for the novel coronavirus.

The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.

Within diagnostics, the firm posted molecular diagnostics revenues of $178.5 million, up 9 percent from $164.3 million in fiscal Q1 2019.

On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.

Revenues of $850.5 million beat the company's prior revenue guidance, as well as the consensus Wall Street estimate.

News items for the in vitro diagnostics industry for the week of Dec. 30, 2019

Pages